Stocks and InvestingStocks and Investing
Thu, August 19, 2021
Wed, August 18, 2021
Tue, August 17, 2021
Mon, August 16, 2021

Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $90 on, Aug 16th, 2021


Published on 2024-10-27 17:39:42 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $93 to $90 on, Aug 16th, 2021.

Matthew has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $75 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $110 on, Tuesday, June 15th, 2021